FDA Clearance Tracker · P160044
ABBOTT REALTIME CMV
Last checked: Nov 19, 2026Latest source record: May 18, 2017 (this decision)Source: openFDAMethods & limitations
Decided
May 18, 2017
Approved (reclassified)
Time to decision
226 days
Received Oct 4, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class II
The decision
- FDA number
- P160044
- Device name
- ABBOTT REALTIME CMV
- Applicant
- Abbott Molecular
- Applicant location
- Des Plaines, IL
- Received
- Oct 4, 2016
- Decided
- May 18, 2017
- Decision
- Approved (reclassified)
- Supplements
- 5 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3180
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the Abbott RealTime CMV test is an in vitro polymerase chain reaction (PCR) assay for the quantitation of cytomegalovirus (CMV) DNA in human EDTA plasma. The Abbott RealTime CMV test is intended for use as an aid in the management of Hematopoietic Stem Cell Transplant patients who are undergoing anti-cytomegalovirus therapy. In this population, serial DNA measurement can be used to assess virological response to anti-cytomegalovirus therapy. The results from the RealTime CMV test must be interpreted within the context of all relevant clinical and laboratory findings. The RealTime CMV test is not intended as a screening test for the presence of CMV DNA in blood or blood products.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PAB. The earliest in FDA's data is P110037, decided Jul 5, 2012.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Abbott Molecular
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Alinity m HCV510(k)
K252102 · Decided Sep 25, 2025 · 84 days after receipt
Device type: Assay, Hybridization And/Or Nucleic Acid Amplification For Detection Of Hepatitis C Rna,Hepatitis C Virus (MZP) · Laboratory Medicine & Pathology
- Alinity m HR HPVPMA supplement
P230003-S006 · Decided Sep 10, 2025 · 264 days after receipt · Panel Track
Device type: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS (MAQ) · Laboratory Medicine & Pathology
K243489 · Decided Jul 28, 2025 · 258 days after receipt
Device type: Nucleic Acid Amplification Test For The Quantitation Of Epstein-Barr Virus (Ebv) Dna (QLX) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.